Natural Killer (NK) cell therapy for cancer, spun off from Maastricht University.
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Acquired by 819 Capital Partners VC firm 819 Capital Partners acquired and invested in Dutch NK-cell-therapy biotech CiMaas out of bankruptcy via its 819 Evergreen Fund I. | — |
Data is community-curated and may be incomplete.